BLOG
Blog
Case Study: Applying Scientific Expertise to Optimize Complex Safety-Focused DDI Studies
Altasciences conducted two drug-drug interaction studies to evaluate a novel cardiovascular therapy’s safety with clopidogrel and warfarin, ensuring safe co-administration.
Blog
30 Years of Innovation in Drug Development: The Evolution of the Contract Research Organization
Explore 30 years of CRO evolution, from preclinical roots to integrated, flexible partnerships—and how Altasciences is shaping the future of drug development.
Blog
Case Study: Achieving a 505(b)(2) Regulatory Approval for Multiple NDA-Enabling Studies
See how Altasciences supported a sponsor’s 505(b)(2) submission with three pivotal studies, driving simulation, bioavailability, and dose-escalation, to deliver critical data.
Blog
7 Tips for Navigating the Complexities of In Vitro NAMs Studies
Discover seven tips from expert toxicologist and consultant Robin Guy on tackling key challenges for in vitro NAMs studies, from data integrity to regulatory acceptance.
Blog
A Professional Perspective on the FDA Roadmap Announcement on “Phasing Out” Animal Testing Requirements
Toxicologist Mary Ellen Cosenza explains the FDA’s 2025 roadmap for phasing out animal testing and its implications for drug development and safety.
Blog
Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte
Martin Turcotte reflects on CYTO 2025, and how spectral cytometry was at the forefront of most conversations.
Blog
Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron
Jean-François (Principal Scientist, MS) and Benjamin (Scientist 1, MD) share key takeaways from attending ASMS 2025.